PVG.L Regulatory News (PVG)

11 Jan 2008 10:33

Ark Therapeutics Group PLC11 January 2008 11 January 2008 Ark Therapeutics Group plc (the "Company") Director Shareholding On 3 January 2008, the Company's Remuneration Committee (which is comprisedwholly of non-executive directors) awarded options over 60,000 ordinary sharesto the Consultant Director of Molecular Medicine, Professor SeppoYla-Herttuala, under the Company's Consultancy Share Option Plan (the"Consultancy Plan"). Options will not be exercisable until at least three years from the date ofissue. Options awarded under the Consultancy Plan have an exercise price of 94pence per ordinary share. No consideration was paid for the grant of options. Following this award, Professor Yla-Herttuala will hold options over 549,999ordinary shares. As a result of the acquisition by the Company of Lymphatix Oy announced earlierthis week, Professor Yla-Herttuala's interest in the Company's shares hasincreased by 132,477 ordinary shares of 1 pence each, representing approximately0.06% of the Company's issued share capital, Following this transaction,Professor Yla-Herttuala owns 3,284,835 ordinary Ark shares, representing 1.6%of the Company's issued share capital. For further information please contact: Ark Therapeutics Group plc +44 (0)20 7388 7722Nick Plummer, Company Secretary This information is provided by RNS The company news service from the London Stock Exchange